ANI Pharmaceuticals offers to acquire Egetis Therapeutics for SEK 5.6 billion

Bitget2026/11/05 06:38

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ANI Pharmaceuticals offered to acquire Egetis Therapeutics for approximately SEK 5.6 billion (USD 560 million), expanding its rare-disease business.
The SEK 11.25-per-share offer represents a 27% premium to Egetis' 60-day volume-weighted average share price.
The transaction implies an enterprise value of approximately USD 434 million, adjusted for estimated net proceeds from Egetis' priority review voucher sale.
Egetis' MCT8-deficiency treatment EMCITATE has estimated peak sales potential exceeding USD 300 million in its approved indication, with patent protection into 2045.
Egetis' board unanimously supports the offer, backed by shareholders controlling approximately 42%; financing combines cash with new JPMorgan Chase debt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050133PRIMZONEFULLFEED9871006) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ANI Pharmaceuticals offers to acquire Egetis Therapeutics for SEK 5.6 billion

You may also like

Crypto prices